|
 |
Volume 3, Number 9 (September 2006) | ||||||
Letter from the Editor |
||||||
547 |
Staying focused on the practical The West Clinic, Memphis, TN This issue is packed with information of immediate practical relevance, from clinical trials to managing side effects, the latest on treatment for multiple myeloma and more.
|
|||||
Community Dialogue |
||||||
553 |
Insurance coverage for rare cancers: the carrier’s perspective
|
|||||
Nursing Management |
||||||
558 |
Managing the side effects of sorafenib and sunitinib Cleveland Clinic Taussig Cancer Center, Cleveland, OH The approval of sorafenib and sunitinib has created a paradigmatic shift in the treatment of metastatic renal cell carcinoma. This article offers a brief overview of the side effects associated with these drugs, guidelines for helping patients resolve their symptoms and, a patient education resource list.
|
|||||
Original Contribution |
||||||
567 |
Emerging therapies for metastatic carcinoma to the liver Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston Advances in patient selection, preoperative imaging, surgical techniques, and systemic therapy have led to improvements in clinical outcomes following resection of hepatic metastases in patients with stage IV colorectal carcinoma.
|
|||||
COMMENTARY Wilshire Oncology Medical Group, Inc., La Verne, CA
| ||||||
Challenging Cases/Rare Cancers |
||||||
575 |
The emerging role of novel therapeutic agents in the management of patients with multiple myeloma Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA This article summarizes current clinical trials for newly diagnosed patients and those with relapsed/refractory MM, as well as therapeutic options for patients who are not candidates for stem-cell transplantation.
|
|||||
Managing Side Effects |
||||||
585 |
Management of febrile neutropenia Division of Infectious Diseases, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA At least half of neutropenic patients who become febrile have an established or occult infection. Because of a lack of inflammatory response, signs and symptoms of infection are often subtle. How to assess and treat.
|
|||||
Current Clinical Trials |
||||||
593 |
Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer (Cancer and Leukemia Group B/Southwest Oncology Group 80405) This article is the first in a new series that details available clinical trials and offers information on how you and your practice can participate. The CALGB/SWOG 80405 trial is designed to assess the optimal combination of biological agents and chemotherapy for the first-line treatment of patients with advanced or metastatic colorectal cancer.
|
|||||
Economics/Practice Management |
||||||
603 |
A dispensing pharmacy: is it right for your community practice? International Oncology Network, Baltimore, MD Advances in patient selection, preoperative imaging, surgical techniques, and systemic therapy have led to improvements in clinical outcomes following resection of hepatic metastases in patients with stage IV colorectal carcinoma.
|
|||||
COMMENTARY National Oncology Alliance, San Francisco, CA
| ||||||
COMMUNITY PERSPECTIVE Oncology Hematology Associates of Central Illinois, Peoria, IL
| ||||||
Technology |
||||||
600 |
Web site review: staying UpToDate Created by a Harvard medical school professor, UpToDate.com offers reliable answers to tough medical questions in a number of fields, including oncology. What’s offered, how much it costs, and an interview with one California community practitioner who uses the site regularly.
| |||||
Washington Update |
||||||
609 |
No quick fix for drug errors, but it can be done Five years after the Institute of Medicine released its last report on drug errors, a new report shows we still have a long way to go before the problem is corrected. What the Federal government is doing, and what you can do too.
| |||||
© 2006 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
||||||
43 kb